At a glance
ClinicalIndex Comparison RecordN/ACompleted· 602 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-centre, Prospective, Observational Study Evaluating Whether Integration of Prognostic and Predictive Algorithms Into Routine Clinical Practice Effect Whether Oncologists Order Multigene Assays in Patients With Early Stage Breast Cancer
In Brief
An observational study for Breast Cancer. Completed, enrolled 602 participants across 6 sites.
Detailed Summary
A broad range of prognostic and predictive tools are available for patients with newly diagnosed early stage breast cancer. These range from free and publicly available mathematical algorithms, through to expensive genomic tests. It is not known how the use of these different scores affects physician decision making with respect to ordering genomic tests, nor how well these algorithms predict for the results of Oncotype DX ® in the real-world setting. This pragmatic study will help to answer these questions.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesCanada
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartMar 2020
Primary CompletionMay 2022
TodayJul 2026
First PostedOct 18, 2019
Enrollment StartMar 6, 2020
Primary CompletionMay 18, 2022
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.7 years ago